Replies to post #539275 on NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

There is only one spore combination trial of which I am aware and it includes Keytruda. Do you have a link to the video ATL. I know you’re careful, but it seems so not consistent with the clinicaltrials.gov database. So definitely want to hear that directly.

[ATLnsider]

This suggests to me that NWBio may partner with Bristol Myers Squibb (BMY) instead of Merck (MRK).

Because BMY is providing some funding, and they ar providing some of the treatments (PD-1 inhibitor & CSF-1 receptor inhibitor) for the UCLA Spore project that combines DCVax-L + PD-1 inhibitor + CSF-1 receptor inhibitor. .

But, it is also possible that NWBio could also partner with both BMY and MRK.

[biosectinvestor]

There was a previous trial for BMY, but it did not go forward and MRK stepped in directly with UCLA.

I think most have thought the two were jockeying. But since the Opdivo/Nivolumab trial with DCVax-L did not start, it appeared BMY was sidelined. The contract was pulled and then the Keytruda trial started instead.

BMY Opdivo/Nivolumab trial:

https://clinicaltrials.gov/ct2/show/NCT03014804

[NOTBOB17]

ATLinsider, I started my GBM quest with TCLN, moved on to PPHM and finally to NWBO.
I am 100% certain this is the real deal and the culmination of my 30 year quest. This will revolutionize cancer treatments for decades!! This week will be epic IMO.

[Lykiri]

October 27, 2022

Linda Liau

"This is our next SPORE trial (DC vaccine/poly-ICLC + anti-PD1 + CSF1-Ri in newly diagnosed GBM patients) but we haven't started it yet."

anti-PD1= Pembrolizumab 400 mg q 6 weeks.